As an emerging modality in biological immunotherapy, Multi-target Cytotoxic T Lymphocytes (MTCA-CTL) immunotherapy not only promotes the expansion of non-MHC-restricted invariant NK-T cells (iNKT), but also selectively directs the proliferation of MHC-restricted, CD8+ antigen-specific CTLs, thereby enhancing tumor‐cell cytotoxicity. Here, CD8A is linked to neoplasm.